Apnimed is a pharmaceutical company focused on developing treatments for obstructive sleep apnea (OSA).

Apnimed

Apnimed is a clinical-stage company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders.

Tao Capital Partners

Morningside Venture Investments

Morningside Ventures

Columbia Seligman Investments

Sectoral Asset Management

Alpha Wave Global

Alpha Wave Ventures

In the United States alone, more than 36 million people living with obstructive sleep apnea (OSA) remain undiagnosed and untreated.  
 
To help spread awareness of OSA symptoms, Project Sleep is launching its first #SleepApneaSquad broadcast, led by sleep apnea advocates and experts. 
 
Tune into the live broadcast on YouTube today at 2 p.m. ET: https://bit.ly/3yvUaAL

Did you know that there is a connection between Type 2 diabetes and obstructive sleep apnea? 80% of people with Type 2 diabetes also have sleep apnea. 

Learn more about sleep apnea and related health issues: 🔗 https://lnkd.in/ecw78Yag

Many people living with obstructive sleep apnea (OSA) delay seeking out diagnosis and treatment for a variety of reasons, from lack of awareness to low acceptance of current treatment options, with at least 80% of people with OSA remaining undiagnosed. 
  
To address this concerning public health gap, Project Sleep has launched the #SleepApneaSquad, a new educational initiative backed by leading clinicians and advocates to help people navigate the complex OSA journey.  

We’re thrilled to support this much needed program which will help support unmet needs in the OSA community. Learn more: https://prn.to/46puNwU

We’re thrilled to share Michele Miller, PharmD has joined our team as Director, Medical Information. With over a decade of experience in the field, Michele will play a key role in elevating relationships with health care personnel and the patient experience while building a best-in-industry Medical Information capability at Apnimed. Welcome, Michele!

Interested in working with us? Explore more Apnimed careers. https://bit.ly/4dO72Bt

Sleep apnea is a common but serious sleep disorder. The disorder is caused by repetitive periods when airflow is interrupted during sleep due to a narrowing or closure to the throat. A complete blockage of airflow is an apnea, and a partial interruption is a hypopnea. Each apnea or hypopnea can result in drops in oxygen levels and brief awakenings or sleep disturbances.

Continue learning: https://lnkd.in/ecw78Yag

Typical symptoms of sleep apnea are snoring, snorting, or gasping during sleep, unrefreshed sleep, and daytime sleepiness. These multiple breathing interruptions may prevent you from sleeping well, leaving you feeling extra tired during the day.

Continue learning: 🔗 https://lnkd.in/ecw78Yag

Metric
Company Name	Apnimed
Symbol
MSH ID	COM:APNIMED
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	US
Stage
Employee Count	69
Website	apnimed.com
LinkedIn	apnimed
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

APNI

COM:APNIMED

Apnimed

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue